169 results on '"Fulladosa X"'
Search Results
2. Evaluation of biopsy changes in the early diagnosis of chronic transplant nephropathy
- Author
-
Serón, D., Moreso, F., Bover, J., Condom, E., Fulladosa, X., Gil-Vernet, S., Grinyo, J. M., Alsina, J., Touraine, J. L., editor, Traeger, J., editor, Bétuel, H., editor, Dubernard, J. M., editor, Revillard, J. P., editor, and Dupuy, C., editor
- Published
- 1997
- Full Text
- View/download PDF
3. Ischemia—reperfusion injury as a risk factor for late kidney graft failure
- Author
-
Grinyó, J. M., Gil-Vernet, S., Moreso, F., Serón, D., Fulladosa, X., Cruzado, J. M., Riera, L., Anunciada, A. I., Hueso, M., Alsina, J., Touraine, J. L., editor, Traeger, J., editor, Bétuel, H., editor, Dubernard, J. M., editor, Revillard, J. P., editor, and Dupuy, C., editor
- Published
- 1997
- Full Text
- View/download PDF
4. Use of mycophenolate in ANCA-associated renal vasculitis: 13 years of experience at a university hospital
- Author
-
Draibe, J., Poveda, R., Fulladosa, X., Vidaller, A., Zulberti, C., Gomà, M., Pujol, R., Ripoll, È., Torras, J., and Grinyó, J.M.
- Published
- 2015
- Full Text
- View/download PDF
5. Donor Structural and Functional Parameters Are Independent Predictors of Renal Function at 3 Months
- Author
-
Ibernon, M., González-Segura, C., Moreso, F., Gomà, M., Serón, D., Fulladosa, X., Torras, J., Garcia-Huete, L., Gil-Vernet, S., Cruzado, J.M., Carrera, M., Duarte, V., and Grinyó, J.M.
- Published
- 2007
- Full Text
- View/download PDF
6. Subclinical rejection impairs glomerular adaptation after renal transplantation
- Author
-
Ibernón, M., Gomá, M., Moreso, F., Fulladosa, X., Hueso, M., Cruzado, J.M., Torras, J., Bestard, O., Grinyó, J.M., and Serón, D.
- Published
- 2006
- Full Text
- View/download PDF
7. Subclinical Rejection Associated with Chronic Allograft Nephropathy in Protocol Biopsies as a Risk Factor for Late Graft Loss
- Author
-
Moreso, F., Ibernon, M., Gomà, M., Carrera, M., Fulladosa, X., Hueso, M., Gil-Vernet, S., Cruzado, J.M., Torras, J., Grinyó, J.M., and Serón, D.
- Published
- 2006
- Full Text
- View/download PDF
8. Reproducibility of the Oxford classification of immunoglobulin A nephropathy, impact of biopsy scoring on treatment allocation and clinical relevance of disagreements: Evidence from the VALidation of IGA study cohort
- Author
-
Bellur, S. S., Roberts, I. S. D., Troyanov, S., Royal, V., Coppo, R., Cook, H. T., Cattran, D., Terroba, Y. A., Asunis, A. M., Bajema, I., Bertoni, E., Bruijn, J. A., Cannata-Ortiz, P., Casartelli, D., Di Palma, A. M., Ferrario, F., Fortunato, M., Furci, L., Gakiopoulou, H., Ljubanovic, D. G., Giannakakis, K., Goma, M., Grone, H. -J., Gutierrez, E., Haider, S. A., Honsova, E., Ioachim, E., Karkoszka, H., Kipgen, D., Maldyk, J., Mazzucco, G., Orhan, D., Ozluk, Y., Pantzaki, A., Perkowska-Ptasinska, A., Riispere, Z., Soderberg, M. P., Steenbergen, E., Stoppacciaro, A., Von Feilitzen, B. S., Tardanico, R., Tesar, V., Maixnerova, D., Lundberg, S., Gesualdo, L., Emma, F., Fuiano, L., Beltrame, G., Rollino, C., Amore, A., Camilla, R., Peruzzi, L., Praga, M., Feriozzi, S., Polci, R., Segoloni, G., Colla, L., Pani, A., Angioi, A., Piras, L., Feehally, J., Barratt, J., Cancarini, G., Ravera, S., Durlik, M., Moggia, E., Ballarin, J., Di Giulio, S., Pugliese, F., Serriello, I., Caliskan, Y., Sever, M., Locatelli, F., Del Vecchio, L., Wetzels, J. F. M., Peters, H., Berg, U., Carvalho, F., da Costa Ferreira, A. C., Maggio, M., Wiecek, A., Ots-Rosenberg, M., Magistroni, R., Topaloglu, R., Bilginer, Y., D'Amico, M., Stangou, M., Giacchino, F., Goumenos, D., Kalliakmani, P., Gerolymos, M., Galesic, K., Geddes, C., Siamopoulos, K., Balafa, O., Galliani, M., Stratta, P., Quaglia, M., Bergia, R., Cravero, R., Salvadori, M., Cirami, L., Fellstrom, B., Kloster Smerud, H., Stellato, T., Egido, J., Martin, C., Floege, J., Eitner, F., Lupo, A., Bernich, P., Mene, P., Morosetti, M., van Kooten, C., Rabelink, T., Reinders, M. E. J., Grinyo, J. M., Fulladosa, X., Cusinato, S., Benozzi, L., Savoldi, S., Licata, C., Mizerska-Wasiak, M., Roszkowska-Blaim, M., Martina, G., Messuerotti, A., Dal Canton, A., Esposito, C., Migotto, C., Triolo, G., Mariano, F., Pozzi, C., Boero, R., and Kilicaslan, I.
- Subjects
medicine.medical_specialty ,IgA nephropathy ,immunosuppression ,kidney biopsy ,Oxford classification, proteinuria ,medicine.medical_treatment ,Biopsy ,030232 urology & nephrology ,Disease ,030204 cardiovascular system & hematology ,Lesion ,03 medical and health sciences ,0302 clinical medicine ,Glomerulonephritis ,Models ,Internal medicine ,medicine ,Humans ,Endocapillary hypercellularity ,Clinical significance ,IGA ,Retrospective Studies ,Observer Variation ,Transplantation ,Models, Statistical ,Proteinuria ,medicine.diagnostic_test ,business.industry ,Patient Selection ,Oxford classification ,Reproducibility of Results ,Glomerulonephritis, IGA ,Immunosuppression ,Statistical ,Prognosis ,Nephrology ,proteinuria ,Glomerular Filtration Rate ,Immunosuppressive Agents ,Cohort ,medicine.symptom ,business - Abstract
Background The VALidation of IGA (VALIGA) study investigated the utility of the Oxford Classification of immunoglobulin A nephropathy (IgAN) in 1147 patients from 13 European countries. Methods. Biopsies were scored by local pathologists followed by central review in Oxford. We had two distinct objectives: to assess how closely pathology findings were associated with the decision to give corticosteroid/immunosuppressive (CS/IS) treatments, and to determine the impact of differences in MEST-C scoring between central and local pathologists on the clinical value of the Oxford Classification. We tested for each lesion the associations between the type of agreement (local and central pathologists scoring absent, local present and central absent, local absent and central present, both scoring present) with the initial clinical assessment, as well as long-term outcomes in those patients who did not receive CS/IS. Results All glomerular lesions (M, E, C and S) assessed by local pathologists were independently associated with the decision to administer CS/IS therapy, while the severity of tubulointerstitial lesions was not. Reproducibility between local and central pathologists was moderate for S (segmental sclerosis) and T (tubular atrophy/interstitial fibrosis), and poor for M (mesangial hypercellularity), E (endocapillary hypercellularity) and C (crescents). Local pathologists found statistically more of each lesion, except for the S lesion, which was more frequent with central review. Disagreements were more likely to occur when the proportion of glomeruli affected was low. The M lesion, assessed by central pathologists, correlated better with the severity of the disease at presentation and discriminated better with outcomes. In contrast, the E lesion, evaluated by local pathologists, correlated better with the clinical presentation and outcomes when compared with central review. Both C and S lesions, when discordant between local and central pathologists, had a clinical phenotype intermediate to double absent lesions (milder disease) and double present (more severe). Conclusion We conclude that differences in the scoring of MEST-C criteria between local pathologists and a central reviewer have a significant impact on the prognostic value of the Oxford Classification. Since the decision to offer immunosuppressive therapy in this cohort was intimately associated with the MEST-C score, this study indicates a need for a more detailed guidance for pathologists in the scoring of IgAN biopsies.
- Published
- 2019
9. Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain
- Author
-
Knobel H, Domingo P, Suarez-Lozano I, Gutierrez F, Estrada V, Palacios R, Antela A, Blanco JR, Fulladosa X, Refollo E, and VACH Cohort
- Subjects
cardiovascular disease ,ageing ,HIV ,chronic kidney disease ,tenofovir - Abstract
Background: The life expectancy of HIV-infected individuals has dramatically improved with potent antiretroviral therapies. However, organ-specific toxicities of some antiretrovirals and persistent inflammation and immune activation due to residual virus replication account for a high burden of age-associated comorbidities in the HIV population. Methods: The prevalence of overt cardiovascular, renal and bone diseases as well as their major risk factors were cross-sectionally examined during the year 2014 in the VACH cohort, a large nationwide population of HIV-infected individuals in Spain. Results: A total of 10,897 HIV-infected patients were examined. Seventy-one point four percent were male and the mean age was 48 years. Mean time since HIV diagnosis was 15.8 years and mean time on antiretroviral therapy was 13.1 years. The proportion of patients with undetectable viral load was 87.1%, whereas 65.7% had CD4 counts >500 cells/mm(3). Overall, cardiovascular, renal and bone disease were recorded in 4.7%, 5.9% and 2.8%, respectively. The prevalence of major risk factors was as follows: smoking 51.3%, alcohol abuse 7.8%, overweight/obesity 42.2%, diabetes 19.9%, dyslipidaemia 72.6%, hypertension 25.6%, and osteoporosis 11.1%. In the subset of patients older than 55 years-old (18%), all figures for overt disease and their major risk factors were significantly greater. Conclusion: Major age-related medical conditions and most of their risk factors are highly prevalent in HIV-infected individuals on long-term antiretroviral therapy in Spain. Preventive actions, including careful selection of antiretroviral agents, should be prioritized in the ageing HIV population. (C) 2018 Elsevier Espana, S.L.U. and Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica. All rights reserved.
- Published
- 2019
10. Reproducibility of the Oxford classification of immunoglobulin A nephropathy, impact of biopsy scoring on treatment allocation and clinical relevance of disagreements: Evidence from the VALidation of IGA study cohort
- Author
-
Bellur, S.S. Roberts, I.S.D. Troyanov, S. Royal, V. Coppo, R. Cook, H.T. Cattran, D. Terroba, Y.A. Asunis, A.M. Bajema, I. Bertoni, E. Bruijn, J.A. Cannata-Ortiz, P. Casartelli, D. Di Palma, A.M. Ferrario, F. Fortunato, M. Furci, L. Gakiopoulou, H. Ljubanovic, D.G. Giannakakis, K. Gomá, M. Gröne, H.-J. Gutiérrez, E. Haider, S.A. Honsova, E. Ioachim, E. Karkoszka, H. Kipgen, D. Maldyk, J. Mazzucco, G. Orhan, D. Ozluk, Y. Pantzaki, A. Perkowska-Ptasinska, A. Riispere, Z. Soderberg, M.P. Steenbergen, E. Stoppacciaro, A. Von Feilitzen, B.S. Tardanico, R. Tesar, V. Maixnerova, D. Lundberg, S. Gesualdo, L. Emma, F. Fuiano, L. Beltrame, G. Rollino, C. Coppo, R. Amore, A. Camilla, R. Peruzzi, L. Praga, M. Feriozzi, S. Polci, R. Segoloni, G. Colla, L. Pani, A. Angioi, A. Piras, L. Feehally, J. Barratt, J. Cancarini, G. Ravera, S. Durlik, M. Moggia, E. Ballarin, J. Di Giulio, S. Pugliese, F. Serriello, I. Caliskan, Y. Sever, M. Locatelli, F. Del Vecchio, L. Wetzels, J.F.M. Peters, H. Berg, U. Carvalho, F. da Costa Ferreira, A.C. Maggio, M. Wiecek, A. Ots-Rosenberg, M. Magistroni, R. Topaloglu, R. Bilginer, Y. D'Amico, M. Stangou, M. Giacchino, F. Goumenos, D. Kalliakmani, P. Gerolymos, M. Galesic, K. Geddes, C. Siamopoulos, K. Balafa, O. Galliani, M. Stratta, P. Quaglia, M. Bergia, R. Cravero, R. Salvadori, M. Cirami, L. Fellstrom, B. Kloster Smerud, H. Ferrario, F. Stellato, T. Egido, J. Martin, C. Floege, J. Eitner, F. Lupo, A. Bernich, P. Menè, P. Morosetti, M. van Kooten, C. Rabelink, T. Reinders, M.E.J. Grinyo, J.M. Fulladosa, X. Cusinato, S. Benozzi, L. Savoldi, S. Licata, C. Mizerska-Wasiak, M. Roszkowska-Blaim, M. Martina, G. Messuerotti, A. Dal Canton, A. Esposito, C. Migotto, C. Triolo, G. Mariano, F. Pozzi, C. Boero, R. Kilicaslan, I.
- Abstract
Background: The VALidation of IGA (VALIGA) study investigated the utility of the Oxford Classification of immunoglobulin A nephropathy (IgAN) in 1147 patients from 13 European countries. Methods. Biopsies were scored by local pathologists followed by central review in Oxford. We had two distinct objectives: to assess how closely pathology findings were associated with the decision to give corticosteroid/immunosuppressive (CS/IS) treatments, and to determine the impact of differences in MEST-C scoring between central and local pathologists on the clinical value of the Oxford Classification. We tested for each lesion the associations between the type of agreement (local and central pathologists scoring absent, local present and central absent, local absent and central present, both scoring present) with the initial clinical assessment, as well as long-term outcomes in those patients who did not receive CS/IS. Results: All glomerular lesions (M, E, C and S) assessed by local pathologists were independently associated with the decision to administer CS/IS therapy, while the severity of tubulointerstitial lesions was not. Reproducibility between local and central pathologists was moderate for S (segmental sclerosis) and T (tubular atrophy/interstitial fibrosis), and poor for M (mesangial hypercellularity), E (endocapillary hypercellularity) and C (crescents). Local pathologists found statistically more of each lesion, except for the S lesion, which was more frequent with central review. Disagreements were more likely to occur when the proportion of glomeruli affected was low. The M lesion, assessed by central pathologists, correlated better with the severity of the disease at presentation and discriminated better with outcomes. In contrast, the E lesion, evaluated by local pathologists, correlated better with the clinical presentation and outcomes when compared with central review. Both C and S lesions, when discordant between local and central pathologists, had a clinical phenotype intermediate to double absent lesions (milder disease) and double present (more severe). Conclusion: We conclude that differences in the scoring of MEST-C criteria between local pathologists and a central reviewer have a significant impact on the prognostic value of the Oxford Classification. Since the decision to offer immunosuppressive therapy in this cohort was intimately associated with the MEST-C score, this study indicates a need for a more detailed guidance for pathologists in the scoring of IgAN biopsies. © 2018 The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
- Published
- 2019
11. Lactic acidosis associated with metformin in patients with moderate to severe chronic kidney disease: study protocol for a multicenter population-based case-control study using health databases
- Author
-
Pedros, C, Avila, M, Gomez-Lumbreras, A, Mariquez, M, Morros, R, Videla, S, Prat-Vallverdu, O, Fuentes, I, Valderrama, A, Aguilera, C, Barriocanal, AM, Saez-Penataro, J, Antonijoan, R, Delgado, CE, Llanos, L, Laredo, L, Aguilar, M, Sanz, T, Hernandez, M, Estevez, JC, Ruiz, S, Murgui, L, Corbella, X, Fulladosa, X, Perez-Maraver, M, Alonso, V, and Mata-Cases, M
- Subjects
Chronic kidney failure ,Lactic acidosis ,Type 2 diabetes mellitus ,Electronic health records ,Case-control studies ,Metformin - Abstract
Background: The use of metformin in patients with type 2 diabetes mellitus has been associated with lactic acidosis. However, the information available in patients with moderate-severe chronic kidney disease is scarce. Methods: The ALIMAR-C2 study is a case-control study to assess the association between metformin and lactic acidosis in patients with type 2 diabetes mellitus and moderate-severe chronic kidney disease. The study will be performed with computerized registered electronic health records from eight Spanish hospitals linked to their corresponding primary care health areas from 2010 to 2016, comprising approximately 22.1 million person-years of follow-up. Logistic regression will be used to assess the crude and adjusted risk of lactic acidosis associated with metformin use overall and stratifying by use and dose categories, and chronic kidney disease stage. The overall case fatality rate of lactic acidosis, as well as the case fatality rate stratified by chronic kidney disease stage, will be calculated. Discussion: The ALIMAR-C2 study will provide useful information about the risk of lactic acidosis in type 2 diabetes mellitus patients with renal impairment using metformin.
- Published
- 2019
12. BIOPSY-PROVEN DIABETIC NEPHROPATHY WORSENS RENAL PROGNOSIS IN DIABETIC PATIENT: RESULTS MULTICENTER STUDY BIODIAB-GLOSEN-GEENDIAB
- Author
-
Bermejo, S, Gonzalez, E, Martin, N, Garcia, R, Linares, T, Poch, E, Esparza, N, Diaz-Encarnacion, M, Irene, A, Navarro, MI, Lopez, K, Ibernon, M, Garcia, N, Lopez, D, Martin-Gomez, A, Praga, M, Galceran, JM, Pascual, J, Fulladosa, X, and Romeo, MJS
- Published
- 2019
13. Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study
- Author
-
Domingo P, Suarez-Lozano I, Gutierrez F, Estrada V, Knobel H, Palacios R, Antela A, Blanco JR, Fulladosa X, and VACH
- Subjects
Ageing ,Human immunodeficiency virus ,Tenofovir disoproxil fumarate ,Spain ,Hypertension ,Diabetes ,Renal insufficiency ,Renal impairment ,Tenofovir - Abstract
Background: The use of combination antiretroviral therapy has led to dramatic improvements in the life expectancy of HIV-infected persons. As result, the HIV population is aging and increasingly facing illnesses typically seen in the elderly, such as chronic kidney disease (CKD). Methods: A retrospective longitudinal study was conducted using data from years 2010 and 2014 in all HIV-infected persons enrolled at the Spanish VACH cohort. We analyzed the prevalence and the predictive factors for developing CKD (estimated glomerular filtration rate, eGFR < 60 mL/min/1.73 m(2)). Results: The CKD prevalence at baseline was 456/8968, 5.1% [4.6-5.6%]. Of 8512 HIV-positive individuals examined without CKD at baseline (73.7% male, median age 44 years-old), 2.15% developed CKD (eGFR < 60 mL/min/1.73 m(2)). The odds ratios [95%Cl] for the independent predictive factors identified were gender (male) 0.54 [0.39-0.75], age (per year) 1.08 [1.07-1.10], AIDS diagnosis 1.40 [1.03-1.91], protease inhibitor-based regimens 1.49 [1.10-2.02], hypertension 1.37 [0.94-1.99], diabetes 1.84 [1.33-2.55] and history of cardiovascular events 1.66 [0.96-2.86]. Conclusions: The prevalence and risk factors for CKD and its progression are high in the VACH cohort. Thus, preventive measures such as control of hypertension, diabetes and obesity, as well as efforts for avoiding exposure to nephrotoxic drugs, including some antiretrovirals, are warranted in this aging HIV population. (C) 2019 Sociedad Espanola de Nefrologia. Published by Elsevier Espana, S.L.U.
- Published
- 2019
14. Glomerular Size in Early Protocol Biopsies is Associated with Graft Outcome
- Author
-
Azevedo, F., Alperovich, G., Moreso, F., Ibernon, M., Gomà, M., Fulladosa, X., Hueso, M., Carrera, M., Grinyó, J. M., and Serón, D.
- Published
- 2005
15. Histologic findings in protocol biopsies performed in stable renal allografts under different immunosuppressive schedules
- Author
-
Moreso, F, Alperovich, G, Fulladosa, X, Gil-Vernet, S, Ibernon, M, Carrera, M, Castelao, A.M, Hueso, M, Grinyo, J.M, and Serón, D
- Published
- 2003
- Full Text
- View/download PDF
16. Autosomal Dominant Tubulointerstitial Kidney Disease: Clinical Presentation of Patients With ADTKD-UMOD and ADTKD-MUC1
- Author
-
Ayasreh, N, Bullich, G, Miquel, R, Furlano, M, Ruiz, P, Lorente, L, Valero, O, Garcia-Gonzalez, MA, Arhda, N, Garin, I, Martinez, V, Perez-Gomez, V, Fulladosa, X, Arroyo, D, Martinez-Vea, A, Espinosa, M, Ballarin, J, Ars, E, and Torra, R
- Abstract
Rationale & Objective: Autosomal dominant tubulointerstitial kidney disease (ADTKD) is a rare underdiagnosed cause of end-stage renal disease (ESRD). ADTKD is caused by mutations in at least 4 different genes: MUC1, UMOD, HNF1B, and REN. Study Design: Retrospective cohort study. Setting & Participants: 56 families (131 affected individuals) with ADTKD referred from different Spanish hospitals. Clinical, laboratory, radiologic, and pathologic data were collected, and genetic testing for UMOD, MUC1, REN, and HNF1B was performed. Predictors: Hyperuricemia, ultrasound findings, renal histology, genetic mutations. Outcomes: Age at ESRD, rate of decline in estimated glomerular filtration rate. Results: ADTKD was diagnosed in 25 families (45%), 9 carried UMOD pathogenic variants (41 affected members), and 16 carried the MUC1 pathogenic mutation c.(428) dupC (90 affected members). No pathogenic variants were identified in REN or HNF1B. Among the 77 individuals who developed ESRD, median age at onset of ESRD was 51 years for those with ADTKD-MUC1 versus 56 years (P = 0.1) for those with ADTKD-UMOD. Individuals with the MUC1 duplication presented higher risk for developing ESRD (HR, 2.24; P = 0.03). The slope of decline in estimated glomerular filtration rate showed no significant difference between groups (-3.0 mL/min/1.73 m(2) per year in the ADTKD-UMOD group versus -3.9 mL/min/1.73 m(2) per year in the ADTKD-MUC1 group; P = 0.2). The prevalence of hyperuricemia was significantly higher in individuals with ADTKDUMOD (87% vs 54%; P = 0.006). Although gout occurred more frequently in this group, the difference was not statistically significant (24% vs 7%; P = 0.07). Limitations: Relatively small Spanish cohort. MUC1 analysis limited to cytosine duplication. Conclusions: The main genetic cause of ADTKD in our Spanish cohort is the MUC1 pathogenic mutation c.(428) dupC. Renal survival may be worse in individuals with the MUC1 mutation than in those with UMOD mutations. Clinical presentation does not permit distinguishing between these variants. However, hyperuricemia and gout are more frequent in individuals with ADTKD-UMOD.
- Published
- 2018
17. Muir-Torré syndrome in a patient with acquired immunodeficiency syndrome
- Author
-
Graells, J., Marcoval, J., Badell, A., Notario, J., and Fulladosa, X.
- Published
- 1996
18. Mortality reduction by post-dilution online-haemodiafiltration: a cause-specific analysis
- Author
-
Nubé, Menso J., Peters, Sanne A E, Blankestijn, Peter J., Canaud, Bernard, Davenport, Andrew, Grooteman, Muriel P C, Asci, Gulay, Locatelli, Francesco, Maduell, Francisco, Morena, Marion, Ok, Ercan, Torres, Ferran, Bots, Michiel L., Moreso, Francesc, Pons, Mercedes, Ramos, Rosa, Mora-Macià, Josep, Carreras, Jordi, Soler, Jordi, Campistol, Josep M., Martinez-Castelao, Alberto, Insensé, B., Perez, C., Feliz, T., Barbetta, M., Soto, C., Mora, J., Juan, A., Ibrik, O., Foraster, A., Nin, J., Fernández, A., Arruche, M., Sánchez, C., Vidiella, J., Barbosa, F., Chiné, M., Hurtado, S., Llibre, J., Ruiz, A., Serra, M., Salvó, M., Poyuelo, T., Maduell, F., Carrera, M., Fontseré, N., Arias, M., Merín, A., Ribera, L., Galceran, J. M., Mòdol, J., Moliner, E., Ramirez, A., Aguilera, J., Alvarez, M., De La Torre, B., Molera, M., Casellas, J., Martín, G., Andres, E., Coll, E., Valles, M., Martínez, C., Castellote, E., Casals, J. M., Gabàs, J., Romero, M., Martinez-Castelao, A., Fulladosa, X., Ramirez-Arellano, M., Fulquet, M., Pelegrí, A., El Manouari, M., Ramos, N., Bartolomé, J., Sans, R., Fernández, E., Sarró, F., Compte, T., Marco, F., Mauri, R., Bronsoms, J., Arnaiz, J. A., Beleta, H., Pejenaute, A., Ríos, J., Lara, J., Ter Wee, P. M., Van Den Dorpel, M. A., Dorval, M., Lévesque, R., Koopman, M. G., Konings, C. J A M, Haanstra, W. P., Kooistra, M., Van Jaarsveld, B., Noordzij, T., Feith, G. W., Peltenburg, H. G., Van Buren, M., Offerman, J. J G, Hoogeveen, E. K., De Heer, F., Van De Ven, P. J., Kremer Hovinga, T. K., Bax, W. A., Groeneveld, J. O., Lavrijssen, A. T J, Schrander-Van Der Meer, A. M., Reichert, L. J M, Huussen, J., Rensma, P. L., Schrama, Y., Van Hamersvelt, H. W., Boer, W. H., Van Kuijk, W. H., Vervloet, M. G., Wauters, I. M P M J, Sekse, I., Toz, Huseyin, Ok, Ebru Sevinc, Kircelli, Fatih, Yilmaz, Mumtaz, Hur, Ender, Demirci, Meltem Sezis, Demirci, Cenk, Duman, Soner, Basci, Ali, Adam, Siddig Momin, Isik, Ismet Onder, Zengin, Murat, Suleymanlar, Gultekin, Yilmaz, Mehmet Emin, Ergin, Mehmet Ozkahya Pinar, Sagdic, Alfert, Kayali, Erkan, Boydak, Can, Colak, Taskin, Caliskan, Sihli, Kaplan, Hakan, Ulas, Hasibe, Kirbiyik, Sait, Berktas, Hakan, Dilbaz, Necati, Cristol, Jean Paul, Leray-Moragues, Hélène, Chenine, Leïla, Picot, Marie Christine, Jaussent, Audrey, Belloc, Claire, Lagarrigue, Mélodie, Chalabi, Lotfi, Debure, Alain, Ouziala, Messaoud, Lefevre, Jean Jacques, Thibaudin, Damien, Mohey, Hesham, Broyet, Christian, Afiani, Aida, Serveaux, Marie Odile, Patrier, Laure, Maurice, François, Rivory, Jean Pierre, Nicoud, Philippe, Durand, Claude, Normand, Michel, Seigneuric, Bruno, Magnant, Eric, Azzouz, Lynda, Islam, Mohamed Shariful, Vido, Sandor, Nzeyimana, Hilaire, Simonin, Danièle, Azymah, Yamina, Farah, Ibrahim, Coindre, Jean Philippe, Puyoo, Olivier, Chabannier, Marie Hélène, Ibos, Richard, Rouleau, Fabienne, Vela, Carlos, Joule, Josiane, Combarnous, François, Turc-Baron, Cécile, Ducret, Francis, Pointet, Philippe, Rey, Isabelle, Potier, Jacky, Bendini, Jean Christophe, Perrin, Franck, Kunz, Kristian, Lefrancois, Gaëlle, Colin, Angélique, Parahy, Sophie, Dancea, Irima, Coupel, Stéphanie, Testa, Angelo, Brunet, Philippe, Lebrun, Gaétan, Jaubert, Dominique, Delcroix, Catherine, Lavainne, Frédéric, Lefebvre, Anne, Guillodo, Marie Paule, Le Grignou, Dominique, Djema, Assia, Maaz, Mehadji, Chiron, Sylvie, Hoffmann, Maxime, Depraetre, Pascale, Haddj-Elmrabet, Atman, Joyeux, Véronique, Fleury, Dominique, Vrigneaud, Laurence, Lemaitre, Vincent, Aguilera, Didier, Guerraoui, Abdallah, Cremault, Alain, Laradi, Achour, Babinet, Francois, VU University Medical Center [Amsterdam], University of Oxford [Oxford], University Medical Center [Utrecht], Fresenius Medical Care Deutschland, University College of London [London] (UCL), Ege university, Alessandro Manzoni Hospital, Hospital Clinic Barcelona, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Universitat Autònoma de Barcelona (UAB), Ege Üniversitesi, Nephrology, ICaR - Circulation and metabolism, Herrada, Anthony, and University of Oxford
- Subjects
Male ,medicine.medical_specialty ,030232 urology & nephrology ,Hemodiafiltration ,030204 cardiovascular system & hematology ,haemodiafiltration ,Convection ,Lower risk ,Sudden death ,convection volume ,[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology ,haemo-diafiltration ,03 medical and health sciences ,0302 clinical medicine ,Renal Dialysis ,cardiovascular disease ,Cause of Death ,Internal medicine ,Journal Article ,medicine ,Humans ,Intensive care medicine ,Aged ,Proportional Hazards Models ,Randomized Controlled Trials as Topic ,Transplantation ,integumentary system ,business.industry ,Mortality rate ,Hazard ratio ,Middle Aged ,[SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology ,mortality ,Confidence interval ,3. Good health ,meta-analysis ,Cardiovascular Diseases ,Nephrology ,Meta-analysis ,Cardiology ,Number needed to treat ,Kidney Failure, Chronic ,Female ,business - Abstract
WOS: 000398117600023, PubMed ID: 28025382, Background. From an individual participant data (IPD) meta-analysis from four randomized controlled trials comparing haemodialysis (HD) with post-dilution online-haemodiafiltration (ol-HDF), previously it appeared that HDF decreases all-cause mortality by 14% (95% confidence interval 25; 1) and fatal cardiovascular disease (CVD) by 23% (39; 3). Significant differences were not found for fatal infections and sudden death. So far, it is unclear, however, whether the reduced mortality risk of HDF is only due to a decrease in CVD events and if so, which CVD in particular is prevented, if compared with HD. Methods. The IPD base was used for the present study. Hazard ratios and 95% confidence intervals for cause-specific mortality overall and in thirds of the convection volume were calculated using the Cox proportional hazard regression models. Annualized mortality and numbers needed to treat (NNT) were calculated as well. Results. Besides 554 patients dying from CVD, fatal infections and sudden death, 215 participants died from 'other causes', such as withdrawal from treatment and malignancies. In this group, the mortality risk was comparable between HD and ol-HDF patients, both overall and in thirds of the convection volume. Subdivision of CVD mortality in fatal cardiac, non-cardiac and unclassified CVD showed that ol-HDF was only associated with a lower risk of cardiac casualties [0.64 (0.61; 0.90)]. Annual mortality rates also suggest that the reduction in CVD death is mainly due to a decrease in cardiac fatalities, including both ischaemic heart disease and congestion. Overall, 32 and 75 patients, respectively, need to be treated by high-volume HDF (HV-HDF) to prevent one all-cause and one CVD death, respectively, per year. Conclusion. The beneficial effect of ol-HDF on all-cause and CVD mortality appears to be mainly due to a reduction in fatal cardiac events, including ischaemic heart disease as well as congestion. In HV-HDF, the NNT to prevent one CVD death is 75 per year., EuDial working group; European Nephrology and Dialysis Institute; Catalan Society of Nephrology; Fresenius Medical Care; Dutch Kidney Foundation [C02.2019]; Fresenius Medical Care, Netherlands; Gambro Lundia AB, Sweden; Dr E.E. Twiss Fund; International Society of Nephrology/Baxter Extramural Grant Program; Netherlands Organization for Health Research and DevelopmentNetherlands Organization for Health Research and Development [170882802]; national grant from the Health Ministry (Programme Hospitalier de Recherche Clinique, PHRC); Gambro through the Catalan Society of Nephrology; Roche Netherlands, The HDF Pooling project was designed, conducted and analysed independently of the financial contributors of the individual studies as listed below. Study data were collected and retained by the investigators and were not available for the financial contributors of the individual studies. S.A.E.P. and the meetings of the representatives of the combined authors of the four studies were financially supported by the EuDial working group. EuDial is an official working group of the European Renal Association-European Dialysis Transplant Association (ERA-EDTA, http://era-edta.org/eudial/European_Dialysis_Working_Group.html). No industry funding was received for any part of or activity related to the present analysis.; The Turkish HDF study was supported by European Nephrology and Dialysis Institute with an unrestricted grant. The study was performed in Fresenius Medical Care haemodialysis clinics in Turkey. ESHOL was supported by The Catalan Society of Nephrology and by grants from Fresenius Medical Care and Gambro through the Catalan Society of Nephrology. The CONTRAST study was supported by a grant from the Dutch Kidney Foundation (Nierstichting Nederland Grant C02.2019), and unrestricted grants from Fresenius Medical Care, Netherlands, and Gambro Lundia AB, Sweden. Additional support was received from the Dr E.E. Twiss Fund, Roche Netherlands, the International Society of Nephrology/Baxter Extramural Grant Program, and the Netherlands Organization for Health Research and Development (ZONMw Grant 170882802). The French HDF study was supported by a national grant from the Health Ministry (Programme Hospitalier de Recherche Clinique, PHRC) as a means to improve care and outcome of elderly chronic disease patients.
- Published
- 2017
- Full Text
- View/download PDF
19. Double kidney transplant
- Author
-
Riera, L, Serón, D, Franco, E, Suárez, J.F, Fulladosa, X, Ramos, R, Gil-Vernet, S, Condóm, E, González, C, Grinyó, J.M, and Serrallach, N
- Published
- 1999
- Full Text
- View/download PDF
20. Mortality reduction by post-dilution online-haemodiafiltration: A cause-specific analysis
- Author
-
Cardiovasculaire Epi Team 5, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Circulatory Health, MS Nefrologie, MS CGO, MS Medische Oncologie, Cancer, Projectafdeling VCI, Secretariaat en overig CTC, AIOS Anesthesiologie, Nubé, Menso J., Peters, Sanne A E, Blankestijn, Peter J., Canaud, Bernard, Davenport, Andrew, Grooteman, Muriel P C, Asci, Gulay, Locatelli, Francesco, Maduell, Francisco, Morena, Marion, Ok, Ercan, Torres, Ferran, Bots, Michiel L., Moreso, Francesc, Pons, Mercedes, Ramos, Rosa, Mora-Macià, Josep, Carreras, Jordi, Soler, Jordi, Campistol, Josep M., Martinez-Castelao, Alberto, Insensé, B., Perez, C., Feliz, T., Barbetta, M., Soto, C., Mora, J., Juan, A., Ibrik, O., Foraster, A., Nin, J., Fernández, A., Arruche, M., Sánchez, C., Vidiella, J., Barbosa, F., Chiné, M., Hurtado, S., Llibre, J., Ruiz, A., Serra, M., Salvó, M., Poyuelo, T., Maduell, F., Carrera, M., Fontseré, N., Arias, M., Merín, A., Ribera, L., Galceran, J. M., Mòdol, J., Moliner, E., Ramirez, A., Aguilera, J., Alvarez, M., De La Torre, B., Molera, M., Casellas, J., Martín, G., Andres, E., Coll, E., Valles, M., Martínez, C., Castellote, E., Casals, J. M., Gabàs, J., Romero, M., Martinez-Castelao, A., Fulladosa, X., Ramirez-Arellano, M., Fulquet, M., Pelegrí, A., El Manouari, M., Ramos, N., Bartolomé, J., Sans, R., Fernández, E., Sarró, F., Compte, T., Marco, F., Mauri, R., Bronsoms, J., Arnaiz, J. A., Beleta, H., Pejenaute, A., Ríos, J., Lara, J., Ter Wee, P. M., Van Den Dorpel, M. A., Dorval, M., Lévesque, R., Koopman, M. G., Konings, C. J A M, Haanstra, W. P., Kooistra, M., Van Jaarsveld, B., Noordzij, T., Feith, G. W., Peltenburg, H. G., Van Buren, M., Offerman, J. J G, Hoogeveen, E. K., De Heer, F., Van De Ven, P. J., Kremer Hovinga, T. K., Bax, W. A., Groeneveld, J. O., Lavrijssen, A. T J, Schrander-Van Der Meer, A. M., Reichert, L. J M, Huussen, J., Rensma, P. L., Schrama, Y., Van Hamersvelt, H. W., Boer, W. H., Van Kuijk, W. H., Vervloet, M. G., Wauters, I. M P M J, Sekse, I., Toz, Huseyin, Ok, Ebru Sevinc, Kircelli, Fatih, Yilmaz, Mumtaz, Hur, Ender, Demirci, Meltem Sezis, Demirci, Cenk, Duman, Soner, Basci, Ali, Adam, Siddig Momin, Isik, Ismet Onder, Zengin, Murat, Suleymanlar, Gultekin, Yilmaz, Mehmet Emin, Ergin, Mehmet Ozkahya Pinar, Sagdic, Alfert, Kayali, Erkan, Boydak, Can, Colak, Taskin, Caliskan, Sihli, Kaplan, Hakan, Ulas, Hasibe, Kirbiyik, Sait, Berktas, Hakan, Dilbaz, Necati, Cristol, Jean Paul, Leray-Moragues, Hélène, Chenine, Leïla, Picot, Marie Christine, Jaussent, Audrey, Belloc, Claire, Lagarrigue, Mélodie, Chalabi, Lotfi, Debure, Alain, Ouziala, Messaoud, Lefevre, Jean Jacques, Thibaudin, Damien, Mohey, Hesham, Broyet, Christian, Afiani, Aida, Serveaux, Marie Odile, Patrier, Laure, Maurice, François, Rivory, Jean Pierre, Nicoud, Philippe, Durand, Claude, Normand, Michel, Seigneuric, Bruno, Magnant, Eric, Azzouz, Lynda, Islam, Mohamed Shariful, Vido, Sandor, Nzeyimana, Hilaire, Simonin, Danièle, Azymah, Yamina, Farah, Ibrahim, Coindre, Jean Philippe, Puyoo, Olivier, Chabannier, Marie Hélène, Ibos, Richard, Rouleau, Fabienne, Vela, Carlos, Joule, Josiane, Combarnous, François, Turc-Baron, Cécile, Ducret, Francis, Pointet, Philippe, Rey, Isabelle, Potier, Jacky, Bendini, Jean Christophe, Perrin, Franck, Kunz, Kristian, Lefrancois, Gaëlle, Colin, Angélique, Parahy, Sophie, Dancea, Irima, Coupel, Stéphanie, Testa, Angelo, Brunet, Philippe, Lebrun, Gaétan, Jaubert, Dominique, Delcroix, Catherine, Lavainne, Frédéric, Lefebvre, Anne, Guillodo, Marie Paule, Le Grignou, Dominique, Djema, Assia, Maaz, Mehadji, Chiron, Sylvie, Hoffmann, Maxime, Depraetre, Pascale, Haddj-Elmrabet, Atman, Joyeux, Véronique, Fleury, Dominique, Vrigneaud, Laurence, Lemaitre, Vincent, Aguilera, Didier, Guerraoui, Abdallah, Cremault, Alain, Laradi, Achour, Babinet, Francois, Cardiovasculaire Epi Team 5, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Circulatory Health, MS Nefrologie, MS CGO, MS Medische Oncologie, Cancer, Projectafdeling VCI, Secretariaat en overig CTC, AIOS Anesthesiologie, Nubé, Menso J., Peters, Sanne A E, Blankestijn, Peter J., Canaud, Bernard, Davenport, Andrew, Grooteman, Muriel P C, Asci, Gulay, Locatelli, Francesco, Maduell, Francisco, Morena, Marion, Ok, Ercan, Torres, Ferran, Bots, Michiel L., Moreso, Francesc, Pons, Mercedes, Ramos, Rosa, Mora-Macià, Josep, Carreras, Jordi, Soler, Jordi, Campistol, Josep M., Martinez-Castelao, Alberto, Insensé, B., Perez, C., Feliz, T., Barbetta, M., Soto, C., Mora, J., Juan, A., Ibrik, O., Foraster, A., Nin, J., Fernández, A., Arruche, M., Sánchez, C., Vidiella, J., Barbosa, F., Chiné, M., Hurtado, S., Llibre, J., Ruiz, A., Serra, M., Salvó, M., Poyuelo, T., Maduell, F., Carrera, M., Fontseré, N., Arias, M., Merín, A., Ribera, L., Galceran, J. M., Mòdol, J., Moliner, E., Ramirez, A., Aguilera, J., Alvarez, M., De La Torre, B., Molera, M., Casellas, J., Martín, G., Andres, E., Coll, E., Valles, M., Martínez, C., Castellote, E., Casals, J. M., Gabàs, J., Romero, M., Martinez-Castelao, A., Fulladosa, X., Ramirez-Arellano, M., Fulquet, M., Pelegrí, A., El Manouari, M., Ramos, N., Bartolomé, J., Sans, R., Fernández, E., Sarró, F., Compte, T., Marco, F., Mauri, R., Bronsoms, J., Arnaiz, J. A., Beleta, H., Pejenaute, A., Ríos, J., Lara, J., Ter Wee, P. M., Van Den Dorpel, M. A., Dorval, M., Lévesque, R., Koopman, M. G., Konings, C. J A M, Haanstra, W. P., Kooistra, M., Van Jaarsveld, B., Noordzij, T., Feith, G. W., Peltenburg, H. G., Van Buren, M., Offerman, J. J G, Hoogeveen, E. K., De Heer, F., Van De Ven, P. J., Kremer Hovinga, T. K., Bax, W. A., Groeneveld, J. O., Lavrijssen, A. T J, Schrander-Van Der Meer, A. M., Reichert, L. J M, Huussen, J., Rensma, P. L., Schrama, Y., Van Hamersvelt, H. W., Boer, W. H., Van Kuijk, W. H., Vervloet, M. G., Wauters, I. M P M J, Sekse, I., Toz, Huseyin, Ok, Ebru Sevinc, Kircelli, Fatih, Yilmaz, Mumtaz, Hur, Ender, Demirci, Meltem Sezis, Demirci, Cenk, Duman, Soner, Basci, Ali, Adam, Siddig Momin, Isik, Ismet Onder, Zengin, Murat, Suleymanlar, Gultekin, Yilmaz, Mehmet Emin, Ergin, Mehmet Ozkahya Pinar, Sagdic, Alfert, Kayali, Erkan, Boydak, Can, Colak, Taskin, Caliskan, Sihli, Kaplan, Hakan, Ulas, Hasibe, Kirbiyik, Sait, Berktas, Hakan, Dilbaz, Necati, Cristol, Jean Paul, Leray-Moragues, Hélène, Chenine, Leïla, Picot, Marie Christine, Jaussent, Audrey, Belloc, Claire, Lagarrigue, Mélodie, Chalabi, Lotfi, Debure, Alain, Ouziala, Messaoud, Lefevre, Jean Jacques, Thibaudin, Damien, Mohey, Hesham, Broyet, Christian, Afiani, Aida, Serveaux, Marie Odile, Patrier, Laure, Maurice, François, Rivory, Jean Pierre, Nicoud, Philippe, Durand, Claude, Normand, Michel, Seigneuric, Bruno, Magnant, Eric, Azzouz, Lynda, Islam, Mohamed Shariful, Vido, Sandor, Nzeyimana, Hilaire, Simonin, Danièle, Azymah, Yamina, Farah, Ibrahim, Coindre, Jean Philippe, Puyoo, Olivier, Chabannier, Marie Hélène, Ibos, Richard, Rouleau, Fabienne, Vela, Carlos, Joule, Josiane, Combarnous, François, Turc-Baron, Cécile, Ducret, Francis, Pointet, Philippe, Rey, Isabelle, Potier, Jacky, Bendini, Jean Christophe, Perrin, Franck, Kunz, Kristian, Lefrancois, Gaëlle, Colin, Angélique, Parahy, Sophie, Dancea, Irima, Coupel, Stéphanie, Testa, Angelo, Brunet, Philippe, Lebrun, Gaétan, Jaubert, Dominique, Delcroix, Catherine, Lavainne, Frédéric, Lefebvre, Anne, Guillodo, Marie Paule, Le Grignou, Dominique, Djema, Assia, Maaz, Mehadji, Chiron, Sylvie, Hoffmann, Maxime, Depraetre, Pascale, Haddj-Elmrabet, Atman, Joyeux, Véronique, Fleury, Dominique, Vrigneaud, Laurence, Lemaitre, Vincent, Aguilera, Didier, Guerraoui, Abdallah, Cremault, Alain, Laradi, Achour, and Babinet, Francois
- Published
- 2017
21. Resumen ejecutivo del documento de consenso sobre el manejo de la patología renal en pacientes con infección por el virus de la inmunodeficiencia humana
- Author
-
Panel de Expertos del Grupo de Estudio de Sida (GESIDA), la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC), la Sociedad Española de Nefrología (SEN), la Sociedad Española de Bioquímica Clínica y Patología Molecular (SEQC), Gorriz JL, Gutiérrez F, Trullàs JC, Arazo P, Arribas JR, Barril G, Cervero M, Cofán F, Domingo P, Estrada V, Fulladosa X, Galindo MJ, Gràcia S, Iribarren JA, Knobel H, López-Aldeguer J, Lozano F, Martínez-Castelao A, Martínez E, Mazuecos MA, Miralles C, Montañés R, Negredo E, Palacios R, Pérez-Elías MJ, Portilla J, Praga M, Quereda C, Rivero A, Santamaría JM, Sanz J, and Miró JM
- Subjects
AIDS, Antiretroviral therapy, Chronic kidney disease, Enfermedad renal crónica, Fármacos antirretrovirales, Human immunodeficiency virus, Insuficiencia renal, Renal failure, Renal toxicity, Renal transplantation, Sida, Tenofovir, Toxicidad renal, Trasplante renal, Virus de la inmunodeficiencia humana ,urologic and male genital diseases - Abstract
The aim of this article is to update the 2010 recommendations on the evaluation and management of renal disease in human immunodeficiency virus (HIV)-infected patients. Renal function should be monitored in all HIV-infected patients. The basic renal work-up should include measurements of serum creatinine, estimated glomerular filtration rate by CKD-EPI, urine protein-to-creatinine ratio, and urinary sediment. Tubular function tests should include determination of serum phosphate levels and urine dipstick for glycosuria. In the absence of abnormal values, renal screening should be performed annually. In patients treated with tenofovir, or with risk factors for chronic kidney disease (CKD), more frequent renal screening is recommended. In order to prevent disease progression, potentially nephrotoxic antiretroviral drugs are not recommended in patients with CKD or risk factors for CKD. The document provides indications for renal biopsy and advises on the optimal time for referral of a patient to the nephrologist. The indications for and evaluation and management of dialysis and renal transplantation are also addressed.
- Published
- 2014
22. Renal Tubular Transporter-Mediated Interactions of HIV Drugs: Implications for Patient Management
- Author
-
Gutierrez, F, Fulladosa, X, Barril, G, and Domingo, P
- Subjects
AIDS ,Creatinine ,Renal toxicity ,HIV ,Kidney ,Antiretroviral therapy ,Renal function - Abstract
Interactions of drugs with renal transporters can reduce the tubular secretion of endogenous products and affect drug pharmacokinetics, efficacy, and toxicity. This review aims to understand the clinical implications of renal transporter-mediated interactions of HIV drugs. These interactions have been fully investigated for nucleoside/nucleotide reverse transcriptase inhibitors, particularly tenofovir disoproxil fumarate, and for some of the newer agents, such as rilpivirine, dolutegravir, and cobicistat. Interactions may include competition, inhibition, or induction of transporters, and interference with renal active secretion of creatinine, the most commonly used marker of renal function. Drug-drug interactions may result in an increased risk of drug toxicity. This interaction is more likely to occur with the protease inhibitors, particularly ritonavir, due to the inhibitory effects of these drugs on specific transporters involved in renal excretion of other drugs. Interactions with the transport of creatinine have been identified with rilpivirine, dolutegravir, and cobicistat. While rilpivirine and dolutegravir inhibit mainly the renal transporter OCT2 in the basolateral membrane of the proximal tubular cell, cobicistat predominantly inhibits the renal transporter MATE1 in the luminal membrane. These interactions can cause mild-to-moderate increases in serum creatinine concentrations and moderate reductions in estimated glomerular filtration rate that do not translate into real decreases in glomerular filtration. To use these drugs safely, clinicians must correctly interpret changes upon initiation of therapy to differentiate these spurious elevations in serum creatinine from clinically significant toxicity. In this article we propose a set of recommendations for clinical use of antiretroviral drugs that interfere with creatinine renal transporters.
- Published
- 2014
23. Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients
- Author
-
Gorriz, JL, Gutierrez, F, Trullas, JC, Arazo, P, Arribas, JR, Barril, G, Cervero, M, Cofan, F, Domingo, P, Estrada, V, Fulladosa, X, Galindo, MJ, Gracia, S, Iribarren, JA, Knobel, H, Lopez-Aldeguer, J, Lozano, F, Martinez-Castelao, A, Martinez, E, Mazuecos, MA, Miralles, C, Montanes, R, Negredo, E, Palacios, R, Perez-Elias, MJ, Portilla, J, Praga, M, Quereda, C, Rivero, A, Santamaria, JM, Sanz, J, Miro, JM, SEIMC, SEN, and Soc Espanola Bioquimica Clinica
- Subjects
AIDS ,Renal failure ,Human immunodeficiency virus ,Chronic kidney disease ,Renal toxicity ,Renal transplantation ,urologic and male genital diseases ,Tenofovir ,Antiretroviral therapy - Abstract
The aim of this article is to update the 2010 recommendations on the evaluation and management of renal disease in human immunodeficiency virus (HIV)-infected patients. Renal function should be monitored in all HIV-infected patients. The basic renal work-up should include measurements of serum creatinine, estimated glomerular filtration rate by CKD-EPI, urine protein-to-creatinine ratio, and urinary sediment. Tubular function tests should include determination of serum phosphate levels and urine dipstick for glycosuria. In the absence of abnormal values, renal screening should be performed annually. In patients treated with tenofovir, or with risk factors for chronic kidney disease (CKD), more frequent renal screening is recommended. In order to prevent disease progression, potentially nephrotoxic antiretroviral drugs are not recommended in patients with CKD or risk factors for CKD. The document provides indications for renal biopsy and advises on the optimal time for referral of a patient to the nephrologist. The indications for and evaluation and management of dialysis and renal transplantation are also addressed. (C) 2014 Elsevier Espana, S.L.U. and Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica. All rights reserved.
- Published
- 2014
24. MO042VALIDATION OF THE 2010 HISTOPATHOLOGIC CLASSIFICATION OF ANCA ASSOCIATED GLOMERULONEPHRITIS IN A SPANISH COHORT
- Author
-
Marco, H., primary, Fulladosa, X., additional, Fernandez-Juárez, G., additional, Quintana, L., additional, Martin, N., additional, Garcia-Osuna, R., additional, Cabre, C., additional, Martin, D., additional, Balius, A., additional, Saurina, A., additional, Praga, M., additional, Ballarin, J., additional, and Diaz-Encarnación, M., additional
- Published
- 2016
- Full Text
- View/download PDF
25. Assessment and management of kidney disease in the HIV-1-infected patient. A practical review
- Author
-
Domingo, P, Knobel, H, Gutierrez, F, Barril, G, and Fulladosa, X
- Subjects
Renal failure ,Antiretroviral drugs ,HIV-1 ,Kidney disease - Abstract
Renal dysfunction in the setting of HIV-1 infection and antiretroviral therapy is an increasingly more common event that has a significant impact on the clinical management of HIV-1-infected patients. The present review examines the epidemiology of renal dysfunction in HIV-1-infected patients, the spectrum of renal injury associated with HIV-1 infection and its treatment, and the various forms of presentation seen in daily clinical practice. As a practical contribution to the management of HIV-1-associated renal dysfunction, guidelines are proposed for assessing the most common kidney-related problems and their management in daily practice. (C) 2008 Elsevier Espana, S.L. All rights reserved.
- Published
- 2010
26. Total glomerular number in stable renal allografts
- Author
-
Fulladosa, X, Moreso, F, Narváez, J.A, Hueso, M, Caldés, A, Gil-Vernet, S, Castelao, A.M, Alsina, J, Grinyó, J.M, and Serón, D
- Published
- 2002
- Full Text
- View/download PDF
27. Predictive value of cyclosporine blood levels during the absorption phase to estimate the area under the curve in stable renal transplant patients
- Author
-
Sabaté, I, Calzada, P, Gil-Vernet, S, Fulladosa, X, Baró, S, González, C, Castro, M.J, Castelao, A.M, and Grinyó, J.M
- Published
- 2002
- Full Text
- View/download PDF
28. FRI0403 Mesangial Proliferative Lupus Nephritis (ISN/RPS CLASS II): Clinical and Prognosis in A Cohort of 45 Patients
- Author
-
Albert, G., primary, Narváez, J., additional, Ricse, M., additional, Estrada, P., additional, Zacarías, A., additional, Pestaña, M., additional, Mora, C., additional, Rozadilla, A., additional, Fulladosa, X., additional, Nolla, J.M., additional, and Rubio Rivas, M., additional
- Published
- 2014
- Full Text
- View/download PDF
29. Renal function reserve in stable grafts and its relationship to renal morphologic parameters
- Author
-
Fulladosa, X., Moreso, F., Narváez, J.A., Condom, E., Torras, J., Alsina, J., Grinyó, J.M., and Serón, D.
- Published
- 1999
- Full Text
- View/download PDF
30. Clinical nephrology / Glomerulonephritis
- Author
-
Plaisier, E., primary, Terrier, B., additional, Karras, A., additional, Lacraz, A., additional, Marie, I., additional, Kahn, J.-E., additional, Le Guenno, G., additional, Benarous, L., additional, Hermine, O., additional, Diot, E., additional, Saadoun, D., additional, Cacoub, P., additional, Casian, A., additional, Walsh, M., additional, Berden, A., additional, Jayne, D., additional, Zwerina, J., additional, Bach, C., additional, Martorana, D., additional, Jatzwauk, M., additional, Hegasy, G., additional, Moosig, F., additional, Bremer, J., additional, Wieczorek, S., additional, Moschen, A., additional, Tilg, H., additional, Neumann, T., additional, Spriewald, B., additional, Schett, G., additional, Vaglio, A., additional, Appel, G., additional, Dooley, M. A., additional, Ginzler, E., additional, Isenberg, D., additional, Wofsy, D., additional, Solomons, N., additional, Lisk, L., additional, Cruzado, J. M., additional, Poveda, R., additional, Ibernon, M., additional, Diaz, M., additional, Fulladosa, X., additional, Carrera, M., additional, Torras, J., additional, Bestard, O., additional, Navarro, I., additional, Ballarin, J., additional, Romero, R., additional, and Grinyo, J. M., additional
- Published
- 2011
- Full Text
- View/download PDF
31. Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy
- Author
-
Cruzado, J. M., primary, Poveda, R., additional, Ibernon, M., additional, Diaz, M., additional, Fulladosa, X., additional, Carrera, M., additional, Torras, J., additional, Bestard, O., additional, Navarro, I., additional, Ballarin, J., additional, Romero, R., additional, and Grinyo, J. M., additional
- Published
- 2011
- Full Text
- View/download PDF
32. ANGIOTENSING CONVERTING ENZIME (ACE) MRNA EXPRESSION IN PROTOCOL BIOPSIES WITH CHRONIC ALLOGRAFT NEPHROPATY (CAN)
- Author
-
Hueso, M, primary, Moreso, F, additional, Navarro, E, additional, Beltrán-Sastre, V, additional, Fulladosa, X, additional, Bestard, O, additional, Ibernón, M, additional, Alia, P, additional, Navarro, M A., additional, Grinyó, J M., additional, and Serón, D, additional
- Published
- 2004
- Full Text
- View/download PDF
33. RELATIONSHIP BETWEEN HISTOLOGICAL LESIONS OBSERVED IN PROTOCOL BIOPSIES AND ARTERIAL RESISTIVE INDEX
- Author
-
Vallejos, A, primary, Serón, D, additional, Moreso, F, additional, Alperovich, G, additional, Cañas, C, additional, Ibernon, M, additional, Lopes, J A., additional, Carrera, M, additional, Lamas, E, additional, Fulladosa, X, additional, Hueso, M, additional, and Grinyó, J M., additional
- Published
- 2004
- Full Text
- View/download PDF
34. MORPHOMETRIC EVALUATION OF DONOR BIOPSIES AND RENAL ALLOGRAFT FUNCTION
- Author
-
Lopes, J A., primary, Serón, D, additional, Moreso, F, additional, Riera, L, additional, Carrera, M, additional, Fulladosa, X, additional, Hueso, M, additional, and Grinyó, J M., additional
- Published
- 2004
- Full Text
- View/download PDF
35. ROLE OF PAF ON THE DEVELOPMENT OF CHRONIC TRANSPLANT NEPHROPATHY INDUCED BY COLD ISCHEMIA IN AN ALLOANTIGEN-INDEPENDENT TRANSPLANT MODEL.
- Author
-
Herrero, I., primary, Torras, J., additional, Cruzado, J. M., additional, Lloberas, N., additional, Riera, M., additional, Condom, E., additional, Merlos, M., additional, Fulladosa, X., additional, Alsina, J., additional, and Grinyo, J. M., additional
- Published
- 2000
- Full Text
- View/download PDF
36. LOW-DOSE CYCLOSPORINE AND MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTS WITH SUBOPTIMAL RENAL FUNCTION
- Author
-
Griny??, JM., primary, Seron, D., additional, Gil-Vernet, S., additional, Hueso, M., additional, Bover, J., additional, Coll, O., additional, Cruzado, J M., additional, Fulladosa, X., additional, Moreso, F., additional, Torras, J., additional, Castelao, A M., additional, and Alsina, J., additional
- Published
- 1998
- Full Text
- View/download PDF
37. LOW-DOSE CYCLOSPORINE AND MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTS WITH SUBOPTIMAL RENAL FUNCTION.
- Author
-
Grinyó, J M., primary, Seron, D., additional, Gil-Vernet, S., additional, Hueso, M., additional, Bover, J., additional, Coll, O., additional, Cruzado, J M., additional, Fulladosa, X., additional, Moreso, F., additional, Torras, J., additional, Castelao, A M., additional, and Alsina, J., additional
- Published
- 1998
- Full Text
- View/download PDF
38. Mycophenolate as Induction Therapy in Lupus Nephritis with Renal Function Impairment.
- Author
-
Rivera, F., Fulladosa, X., Poveda, R., Frutos, M.A., García-Frías, P., Ara, J., Illescas, L., López-Rubio, E., Mérida, E., Carreño, A., Ballarín, J., Fernández-Juárez, G., Baltar, J., Ramos, C., Pons, S., Oliet, A., Vigil, A., Praga, M., and Segarra, A.
- Abstract
Background: Mycophenolate (MF) is effective as induction therapy for lupus nephritis (LN) in patients with normal renal function; however, little is known about its role in patients with impaired renal failure. The purpose of this study was to evaluate the response to MF in LN and its association with baseline renal function. Methods: Data were obtained for 90 patients from 12 Spanish renal units who were receiving MF as induction therapy for LN. Patients were classified into 2 groups: group 1 (estimated glomerular filtration rate [eGFR] ≥60 ml/min/1.73 m
2 ) and group 2 (eGFR <60 ml/min/ 1.73 m2 ). The primary outcome measure was the percentage of patients who achieved any response and its relationship with initial eGFR. The secondary outcome measures were the percentage of patients who achieved a complete response (CR) or partial response (PR) and the appearance of relapses during treatment and side effects. Results: At initiation of MF treatment, there were no differences in the main parameters between group 1 (n = 63; eGFR 87 ± 23 ml/min/ 1.73 m2 ) and group 2 (n = 27; eGFR 44 ± 12 ml/min/1.73 m2 ). Exposure to prednisone and MF was similar. The percentages of patients who achieved a response in groups 1 and 2 were, respectively, 69.2 and 43.8% at 6 months and 81.3 and 73.7% at 12 months. CR was more frequent in group 1, whereas PR was similar in both groups. Four patients relapsed and side effects were unremarkable. Conclusions: MF is effective and safe as induction therapy for LN, and response is even achieved in patients with baseline renal impairment. Copyright © 2012 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
39. Donor age and delayed graft function as predictors of renal allograft survival in rejection-free patients.
- Author
-
Moreso, F, Serón, D, Gil-Vernet, S, Riera, L, Fulladosa, X, Ramos, R, Alsina, J, and Grinyó, JM
- Abstract
Background.Transplant recipients of kidneys harvested from old donors have a high incidence of delayed graft function (DGF) and a poor graft outcome. This result is partly explained by the increased incidence of acute rejection in patients suffering from DGF. However, the long-term impact of donor age and DGF in rejection free renal transplants is not well established. The aim of the present work is to evaluate the impact of donor age and DGF on long-term outcome in renal transplant with or without acute rejection. [ABSTRACT FROM PUBLISHER]
- Published
- 1999
- Full Text
- View/download PDF
40. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with subop-timal renal function
- Author
-
Hueso, M., Bover, J., Seron, D., GiI-Vernet, S., Sabate, I., Fulladosa, X., Ramos, R., Coil, O., Aisina, J., and Grinyo, J.M.
- Published
- 1998
- Full Text
- View/download PDF
41. Recipient body surface area as a predictor of posttransplant renal allograft evolution.
- Author
-
Moreso, F., Seron, D., Anunciada, A. I., Hueso, M., Ramon, J. M., Fulladosa, X., Gil-Vernet, S., Alsina, J., and Grinyo, J. M.
- Published
- 1998
- Full Text
- View/download PDF
42. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft.
- Author
-
Grinyó, JM, Gil-Vernet, S, Seron, D, Hueso, M, Fulladosa, X, Cruzado, JM, Moreso, F, Fernandez, A, Torras, J, Riera, L, Castelao, AM, and Alsina, J
- Abstract
Background.In renal transplantation the beneficial immunosuppressive effects of cyclosporin (CsA) may be curtailed by its nephrotoxicity, specially in patients receiving a cadaveric allograft from suboptimal donors or at risk of delayed graft function. Mycophenolate mofetil (MMF) and antithymocyte globulin (ATG) have each demonstrated to be potent immunosuppressants in renal transplantation. In a prospective analysis we have studied the results at 6 months of the combination of MMF, ATG and low-dose steroids in patients with low immunological risk receiving a first cadaveric renal allograft from a suboptimal donor or at risk of delayed graft function. [ABSTRACT FROM PUBLISHER]
- Published
- 1998
- Full Text
- View/download PDF
43. Serial Protocol Biopsies to Quantify the Progression of Chronic Transplant Nephropathy in Stable Renal Allografts
- Author
-
Moreso, F., Lopez, M., Vallejos, A., Giordani, C., Riera, L., Fulladosa, X., Hueso, M., Alsina, J., Grinyó, J., and Serón, D.
- Abstract
Aim: To evaluate the utility of intimal thickness and interstitial width as a primary efficacy variable in the design of clinical trials aimed to modify the natural history of chronic allograft nephropathy.Methods: A donor and a 4-month protocol biopsy were evaluated in 40 stable grafts according to the Banff schema. In 27 patients, a second protocol biopsy was done at 1 yr. Arterial intimal volume fraction (Vvintima/artery) and cortical interstitial volume fraction (Vvinterstitium/cortex) were estimated with a point counting technique.Results: Chronic Banff scores increased during follow-up, while acute scores reached its peak at 4 months. Vvintima/artery and Vvinterstitium/cortex significantly increased at 4 months, but not at 1 yr. Vvintima/artery at 4 months correlated with donor Vvintima/artery (r = 0.57, p < 0.001), histocompatibility (r = 0.38, p = 0.01) and serum cholesterol (r = 0.31, p = 0.047). Vvinterstitium/cortex at 4 months correlated with recipient body surface area (r = 0.44, p = 0.004) and delayed graft function (p = 0.016). Power calculations showed that Vvintima/artery and Vvinterstitium/cortex allow an important reduction in minimum sample size of a hypothetical trial aimed to prevent chronic allograft nephropathy.Conclusions: Intimal thickening and interstitial widening progresses rapidly during the first 4 months after transplantation and slowly thereafter. These parameters can be considered as a primary efficacy variable in trials aimed to prevent chronic allograft nephropathy.
- Published
- 2001
- Full Text
- View/download PDF
44. Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy
- Author
-
Seron, D., Moreso, F., Ramon, Jm, Miguel Hueso, Condom, E., Fulladosa, X., Bover, J., Gil-Vernet, S., Castelao, Am, Alsina, J., and Grinyo, Jm
45. Course of three biochemical bone markers after kidney transplantation
- Author
-
Mt, Gonzalez, Bonnin R, Jm, Cruzado, Garcia R, Francesc Moreso, Fulladosa X, Alsina J, Ma, Navarro, and Jm, Griñó
- Subjects
Male ,Time Factors ,Osteocalcin ,Alkaline Phosphatase ,Kidney Transplantation ,Peptide Fragments ,Adrenal Cortex Hormones ,Parathyroid Hormone ,Creatinine ,Cyclosporine ,Humans ,Female ,Biomarkers ,Procollagen ,Follow-Up Studies
46. Secondary hyperparathyroidism and acute ischemic posttransplant renal failure
- Author
-
Cruzado, J. M., Gonzalez, M. T., Gil-Vernet, S., Seron, D., Castelao, A. M., Andres, E., Bonnin, R., Fulladosa, X., Torras, J., Francesc Moreso, Alsina, J., and Grinyo, J. M.
47. Splicing alterations in human renal allografts: detection of a new splice variant of protein kinase Par1/Emk1 whose expression is associated with an increase of inflammation in protocol biopsies of transplanted patients
- Author
-
Hueso M, Beltran V, Francesc Moreso, Ciriero E, Fulladosa X, Jm, Grinyó, Serón D, and Navarro E
48. Secondary hyperparathyroidism and acute ischemic posttransplant renal failure
- Author
-
Jm, Cruzado, Mt, González, Gil-Vernet S, Serón D, Am, Castelao, Andrés E, Bonnin R, Fulladosa X, Torras J, and Francesc Moreso
- Subjects
Adult ,Male ,Reoperation ,Chi-Square Distribution ,Hyperparathyroidism ,Kidney Transplantation ,Tissue Donors ,Postoperative Complications ,Parathyroid Hormone ,Creatinine ,Cadaver ,Humans ,Female ,Treatment Failure ,Glomerular Filtration Rate ,Retrospective Studies
49. ROLE OF PAF ON THE DEVELOPMENT OF CHRONIC TRANSPLANT NEPHROPATHY INDUCED BY COLD ISCHEMIA IN AN ALLOANTIGENINDEPENDENT TRANSPLANT MODEL.
- Author
-
Herrero, I., Torras, J., Cruzado, J. M., Lloberas, N., Riera, M., Condom, E., Merlos, M., Fulladosa, X., Alsina, J., and Grinyo, J. M.
- Published
- 2000
50. LOWDOSE CYCLOSPORINE AND MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTS WITH SUBOPTIMAL RENAL FUNCTION
- Author
-
Grinyó, JM., Seron, D., GilVernet, S., Hueso, M., Bover, J., Coll, O., Cruzado, J M., Fulladosa, X., Moreso, F., Torras, J., Castelao, A M., and Alsina, J.
- Published
- 1998
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.